Hypofractionated Radiation Therapy After Mastectomy in Patients With Stage IIa-IIIa Breast Cancer

Clinical Trial Title

Hypofractionated radiation therapy after mastectomy in preventing recurrence in patients with stage IIa-IIIa breast cancer.

National Clinical Trial Number:


Clinical Trial Protocol Description:

This study is accepting patients at both Rush University Medical Center and Rush Copley Medical Center. Please see contact information below to join the study at one location.

This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have histologically confirmed invasive carcinoma of the breast of any of the following histologies: ductal, lobular, mammary, medullary, or tubular.
  • Have had no prior therapeutic radiation therapy to the chest, neck or axilla. Prior radioactive oral iodine is permitted.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

You will be excluded from the study if any of the following criteria apply to you:

  • Have clinical or radiological evidence of metastatic disease.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator at Rush University Medical Center

Parul Barry, MD

Rush University Medical Center Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Investigator at Rush Copley Medical Center

Joseph T. Meschi, MD

Rush Copley Medical Center Contact Information

Amanda Baker